AI Article Synopsis
- Nontuberculous mycobacteria (NTM) were found in a study of 45,891 samples from patients initially diagnosed with pulmonary tuberculosis between 2004 and 2009.
- Of the 10,041 culture-positive samples, only 208 were identified as MOTT, which is about 2.1% of the pulmonary samples.
- Among the identified cases, the most common causative agents were M. avium complex, M. abscessus, and M. kansasii, highlighting the need for accurate diagnosis and treatment strategies for infections caused by these mycobacteria.
Article Abstract
Nontuberculous mycobacteria were identified from 45891 samples of 19553 patients with a prediagnosis of pulmonary tuberculosis between November 2004 and January 2009. Among 10041 (21.9%) culture positive samples, 208 (2.1%) pulmonary samples recovered from 77 individual patients were differentiated as mycobacteria other than tuberculosis (MOTT). Proportion of mycobacteria evaluated as causative agent for clinical infection were found as 0.16% (n = 31), mostly M. avium complex, M. abscessus and M. kansasii. Additionally, M. fortuitum-peregrinum complex, M. simiae, M. szulgai / intermedium and M. scrofulaceum were found as causative agent in 2, 2, 2 and 1 patient, respectively. Identification of infections caused by environmental or opportunistic pathogen mycobacteria is required in rapid and accurate diagnosis, infection control and treatment planning of infections caused by M. tuberculosis complex and/or MOTT.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oncolytic measles virus-induced cell killing in radio-resistant and drug-resistant nasopharyngeal carcinoma.
Malays J Pathol
December 2024
Universiti Tunku Abdul Rahman, M. Kandiah Faculty of Medicine and Health Sciences, Department of Pre-clinical Sciences, Bandar Sungai Long, 43000, Kajang, Selangor, Malaysia.
Introduction: The current first-line therapy for nasopharyngeal carcinoma (NPC) is often associated with long-term complications. Oncolytic measles virus (MV) therapy offers a promising alternative to cancer therapy. This study aims to investigate the efficacy of MV in killing NPC cells in vitro, both with or without resistance to radiation and drug therapy.
View Article and Find Full Text PDFIdentification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.
Malays J Pathol
December 2024
National Institutes of Health, Institute for Medical Research, Cancer Research Centre, Haematology Unit, 40170 Shah Alam, Selangor, Malaysia.
Introduction: The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.
View Article and Find Full Text PDFOsteoarthritis: An integrative overview from pathogenesis to management.
Malays J Pathol
December 2024
Universiti Kebangsaan Malaysia, 43600 Bangi, Faculty of Medicine, Department of Pharmacology, 56000 Cheras, Kuala Lumpur, Malaysia.
Osteoarthritis (OA) is a prevalent degenerative joint disease characterised by cartilage and subchondral bone breakdown, impacting millions worldwide. This review provides an overview of the complex aetiology of OA, integrating biochemical, mechanical, and genetic factors. It also emphasises a multifaceted management approach, combining non-pharmacological, pharmacological, and surgical treatments.
View Article and Find Full Text PDFChemoprevention of natural product against oral cancer: A comprehensive review.
Malays J Pathol
December 2024
Universiti Sains Malaysia, School of Dental Sciences, Health Campus, Kubang Kerian, Kelantan, Malaysia.
Introduction: Oral cancer is considered the sixth most common form of cancer worldwide. It causes significant morbidity and mortality, especially in low socioeconomic status groups. However, Cancer chemoprevention encompasses the use of specific compounds to suppress the growth of tumours or inhibit carcinogenesis.
View Article and Find Full Text PDF[Chondroprotective therapy and adjuvant support for patients with chronic lower back pain].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
International University of Restorative Medicine, Moscow, Russia.
The trend of an annual increase in the detection of new cases of osteoarthritis (OA) and an increase in the number of patients with chronic lower back pain (LBP) calls for the search for new drugs and pharmaconutraceuticals with anti-inflammatory and chondroprotective properties. In 2019, approaches to the treatment of pain in OA significantly changed. In international and Russian clinical guidelines (CG), pharmaconutraceutical chondroitin sulfate (CS) and glucosamine sulfate (GS) are recommended for OA of different localization as a basic therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!